Abstract 2601
Background
Immune checkpoint inhibitors (ICIs) acting against CTLA-4 and PD-1 represent a strenght therapy in patients (pts) with metastatic melanoma (MM). Antineoplastic activity of ICIs through the activation of immune cells in tumor lesions raised challenge in evaluation of treatment response by imaging. Aim of this study was to compare diagnostic accuracy of different 18F-FDG PET/CT parameters (Metabolic Tumor Volume, MTV; Total Lesion Glycolisis, TLG; Maximum Standardised Uptake Value, SUVmax) to predict therapy response and clinical outcome in pts with MM treated with Ipilimumab (Ipi) and Nivolumab (Nivo) or Pembrolizumab (Pem) and to check for accuracy differences specific for the class of treatment.
Methods
57 MM pts receiving Ipi (25) or PD-1 inhibitors (Nivo 19; Pem 13) who performed a 18F-FDG PET/CT scan at the beginning (PET0) and after completion of Ipi or during anti PD-1 (PET1), were retrospectively evaluated. Response at PET1 was classified as PD, SD, PR and CR according to RECIST 1.1, EORTC criteria and by percentage change of MTV and TLG (cut off values: +43% for PD and -43% for PR, calculated by ROC analysis) of up to 5 target lesions. PET Response Evaluation Criteria for Immunotherapy (PERCIMT) were assessed alone and with the previously described parameters. Performance of each criteria at PET1 to predict pts having clinical benefit (CR, PR and SD) and no clinical benefit (PD) at 6 months since starting ICIs were assessed and correlated to time-to-progression.
Results
For Ipi pts group, best predictors of response were: variation of MTV (Sensitivity 1; Specificity 0.84; accuracy 0.96) and TLG (Se 0.89; Sp; 93.8; acc 0.92), with PERCIMT criteria for progressive disease. In anti-PD1 group overlapping predictivity values were found for EORTC, MTV and TLG (Se 0.95; Sp 1; Acc 0.97). Reliability of above parameters was also confirmed in predicting pts progression free survival at 12 and 24 months.
Conclusions
18F-FDG PET/CT performed 3 months later the first administration could predict response to ICIs and long-term patient clinical outcome. Performance of 18F-FDG PET/CT parameters and criteria in predicting response to ICIs is influenced by the class of treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Local Ethic committee.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5822 - Greek nursing students experience facing death in clinical practice
Presenter: Maria Dimoula
Session: Poster Display session 3
Resources:
Abstract
2866 - HOPEVOL: Hospice care appropriate to the wishes and needs of patients in the palliative terminal phase.
Presenter: Merel van Klinken
Session: Poster Display session 3
Resources:
Abstract
829 - Mindfulness-based stress reduction in early palliative care for advanced cancer patients : an italian single-centre study. MINDEEP
Presenter: Emilia Gianotti
Session: Poster Display session 3
Resources:
Abstract
2702 - Optimising Inpatient Oncology Care
Presenter: Lisa Judge
Session: Poster Display session 3
Resources:
Abstract
1527 - Analysis on the Implementation Results of Family Sickbed for Oncology Patients in Dongshi Township Health Centers from 2015 to 2017
Presenter: Yayu Huang
Session: Poster Display session 3
Resources:
Abstract
2054 - Exploring needs for palliative care and quality of life for oncology patients with advanced disease who undergo radiotherapy
Presenter: Foteini Antonopoulou
Session: Poster Display session 3
Resources:
Abstract
5605 - Cytotoxic contamination in cancer care settings – Risks and safety awareness among cancer nurses
Presenter: Sandra Lundman Vikberg
Session: Poster Display session 3
Resources:
Abstract
5769 - Understanding Chemotherapy - group education sessions prior to commencing chemotherapy
Presenter: Aileen McHale
Session: Poster Display session 3
Resources:
Abstract
2620 - Estimation of HPQ-based absenteeism and presenteeism in cancer patients via ResearchKit
Presenter: Shunsuke Kondo
Session: Poster Display session 3
Resources:
Abstract
4705 - Identifying falls-related variables and risk factors in hospitalised cancer patients
Presenter: Maria Montserrat Martí Dillet
Session: Poster Display session 3
Resources:
Abstract